

University of Massachusetts Medical School
eScholarship@UMMS

UMass Center for Clinical and Translational
Science Research Retreat

2014 UMass Center for Clinical and
Translational Science Research Retreat

May 20th, 12:30 PM


Plasma microRNAs are Associated with Atrial Fibrillation (the miRhythm Study) and Change After Catheter-ablation

David D. McManus
University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

 Part of the [Cardiology Commons](#), [Cardiovascular Diseases Commons](#), [Genetic Phenomena Commons](#), [Genetics and Genomics Commons](#), and the [Translational Medical Research Commons](#)

McManus DD, Tanriverdi K, Lin H, Esa N, Kinno M, Lee R, Mandapati D, Tam S, Ellinor PT, Keaney JF, Benjamin EJ, Ambros VR, Freedman JE. (2014). Plasma microRNAs are Associated with Atrial Fibrillation (the miRhythm Study) and Change After Catheter-ablation. UMass Center for Clinical and Translational Science Research Retreat. Retrieved from https://escholarship.umassmed.edu/cts_retreat/2014/posters/99

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](#).
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

Plasma microRNAs are associated with atrial fibrillation (the miRhythm Study) and change after catheter-ablation

David D. McManus, MD, MSc;^{1,2,3} Kahraman Tanriverdi, PhD;¹ Honghuang Lin PhD;^{2,4} Nada Esa MD;¹ Menhel Kinno MD;¹ Rosalind Lee, MS;⁸ Divakar Mandapati MD, Stanley Tam MD, MBA, Patrick T. Ellinor MD, PhD,^{9,10} John F. Keaney, Jr. MD;¹ Emelia J. Benjamin MD, MSc;^{5,6,7} Victor Ambros, PhD;⁸ Jane E. Freedman, MD^{1,2}

- ¹ Cardiology Division, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
² National Heart Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA, USA
³ Epidemiology Division, Department of Quantitative Health Sciences, University of Massachusetts Medical School Worcester, MA
⁴ Computational Biomedicine Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
⁵ Section of Cardiovascular Medicine, Department of Medicine, Boston University, Boston, MA, USA
⁶ Preventive Medicine Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
⁷ Epidemiology Department, Boston University School of Public Health, Boston, MA, USA
⁸ Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA
⁹ Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, USA
¹⁰ Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA, USA

Short title: Circulating microRNAs and Atrial Fibrillation

Article Type: Original Research

This work was supported by 1U01HL105268-01 and KL2RR031981 (DDM), N01-HC 25195, 6R01-NS 17950; RFA-HL-12-008 (JEF, EM), RO1 HL087201A (JEF, KT) RFA-HL-12-008 (JEF) and 1RO1 HL64753; R01 HL076784; 1 R01 AG028321 (EJB) from the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Division of Intramural Research, National Heart, Lung, and Blood Institute of the National Institutes of Health, Bethesda, MA.

Conflicts of interest: None

Corresponding author:

David D. McManus, MD ScM
Assistant Professor of Medicine
Cardiology Division
University of Massachusetts Medical School
Worcester, MA 01655
tel 774-441-6611; fax 774-442-6959
mcmansud@umhc.org

Background: Atrial fibrillation (AF) is the most common dysrhythmia in the U.S. and Europe. Few biomarkers exist to identify individuals at risk for AF. Cardiac microRNAs (miRNAs) have been implicated in susceptibility to AF and are detectable in the circulation. Nevertheless, data are limited on how circulating levels of miRNAs relate to AF or change over time after catheter- ablation.

Methods: In 211 miRhythm participants (112 with paroxysmal or persistent AF; 99 without AF), we quantified plasma expression of 86 miRNAs associated with cardiac remodeling or disease by high-throughput quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We used qRT-PCR to examine change in plasma miRNA expression from baseline to 1-month after ablation in 47 participants. We also quantified expression of the 20 most variable miRNAs in atrial tissue in 31 participants undergoing cardiac surgery.

Results: The mean age of the miRhythm cohort was 59 years and 58% of participants were men. 21 miRNAs differed significantly between participants with AF and those with no AF in regression models adjusting for known AF risk factors (p value of ≤ 0.0006). Several miRNAs associated with AF, including miR-21, miR-29a, miR-122, miR-150, miR-320, and miR-92a, regulate expression of genes implicated in the pathogenesis of AF. Levels of 33 miRNAs, including 14 associated with AF, changed significantly between baseline and 1-month after catheter ablation (p value of ≤ 0.0006). Although all AF-related plasma miRNAs were expressed in atrial tissue, only miR-21 and miR-411 differed significantly with respect to preoperative AF status.

Conclusions: Plasma levels of miRNAs associated with heart disease and cardiac remodeling were related to AF and changed after catheter-ablation. Our study suggests that AF has a unique circulating miRNA profile and that this profile is influenced by catheter-ablation.